Infection following inflatable penile prosthesis placement: a real-world comparison of device selection and patient...

Advancements in device design have reduced infectious complications following inflatable penile prosthesis (IPP) implantation. This study evaluated infection rates among two models of IPP devices available in the United States, AMS 700™ and Titan^®, using real-world data.

Patients aged ≥18 years from the Premier PINC AI™ Healthcare Database who underwent IPP insertion with either AMS 700 or Titan between 2016 and 2022 were included. Twelve published risk factors for IPP infection [age >75 years, smoking, human immunodeficiency virus (HIV), diabetes, pelvic radiation, urinary diversion, spinal cord injury, obesity, concomitant circumcision, and Peyronie's disease] were used to characterize patients. The association between device model and infection rates was assessed with Cox proportional hazards regression.

In total, 3,636 AMS 700 and 2,830 Titan patients were identified; 26.9% of AMS 700 patients had ≥1 risk factor compared to 19.2% of Titan patients (P<0.001). Patients in the AMS 700 group had higher rates of type 2 diabetes (10.7% vs. 6.0%, P<0.001), obesity (5.6% vs. 2.9%, P<0.001), and Peyronie's disease (2.3% vs. 1.6%, P=0.04). Infection rates were 1.8% (AMS 700) vs. 2.9% (Titan) at 180 days post-IPP and 2.5% (AMS 700) vs. 3.3% (Titan) at a median follow-up of 3 years (P=0.047).

AMS 700 patients experienced significantly lower infection rates in both the short- and long-term period post IPP implantation compared to Titan patients, despite having a higher prevalence of known risk factors for IPP infection. These findings suggest that other factors, including device selection, may influence device infection beyond intrinsic patient characteristics.